Speaker Profile

PhD, FRSM, Chief Scientific Officer, Oxford BioDynamics

Alexandre is a molecular biologist, with the main interest in regulatory genome architecture. He is a cofounder of Oxford BioDynamics and a designer of its EpiSwitch biomarker platform. Alexandre obtained his PhD in cell biology from University College, London (with the Imperial Cancer Research Fund Laboratories). He spent six years of research at the Robert Wood Johnson Medical School UMDNJ, NJ, funded by the Howard Hughes Medical Institute. Upon return to England, he established the Nuclear Dynamics research laboratory at the Sir William Dunn School of Pathology, University of Oxford, becoming University Academic Fellow (Research Council UK) and Senior Fellow of Exeter College. Alexandre is a Fellow of the Royal Society of Medicine.

3D Genomic Liquid Biopsy: Predictive, Prognostic and Diagnostic Biomarkers
EpiSwitch 3D Genomic bloodbased platform: from fundamental biology to systemic clinical biomarkers;EpiSwitch CiRT (Checkpoint Inhibitor Response Test): clinical blood test for prediction of systemic response to PD1L1 immune checkpoint inhibitors; EpiSwitch Prostate Screening Test (PSE): highly accurate, multivariant clinical blood test for prostate cancer screening

Clinical Dx Showcase:
Oxford BioDynamics

Oxford BioDynamics Plc (OBD) is a global biotechnology company, advancing personalized healthcare by commercializing precision medicine tests. The Company's product portfolio is based on a proprietary 3D genomic biomarker platform, EpiSwitch®, built for the prediction of response to therapy, patient prognosis and disease diagnosis.

 Session Abstract – PMWC 2024 Silicon Valley

Showcase Track S2 - January 24 9.30 A.M.-1.45 P.M.,Showcase Track S2 - January 25 9.00 A.M.-4.15 P.M.,Showcase Track S2 - January 26 9.00 A.M.-2.45 P.M.

The PMWC 2024 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.

  • Clinical Dx/Oncology (including Liquid Biopsy)
  • Clinical Dx/Cardio Vascular
  • Clinical Dx/Neurodegenerative


Add Names/PO on Receipt

Apply to Speak at PMWC Silicon Valley by JUL. 18TH

The PMWC team will reply back to a suitable company/topic with an official request for talk/speaker details.

Contact Us:

Fields marked with an * are required 

Contact Us:

Fields marked with an * are required 

Discover What's Next in Precision Medicine!

Join our community today for the latest news, exclusive interviews, and unique insights from world-renowned speakers and experts

Contact Us:

Fields marked with an * are required 

Discount also depends on group size. The bigger group – the bigger discount.

Trouble Registering

Fields marked with an * are required

Stay Tuned For More Information.

Sign up for occasional updates on upcoming conferences, news, and other information. 

Get Updates:

Submit to Speak in the PMWC Showcase

Fields marked with an * are required